Differences in proliferative capacity of primary human acute myelogenous leukaemia cells are associated with altered gene expression profiles and can be used for subclassification of patients

Cell Proliferation

Volumn 46, Issue 5, 2013, Pages 554-562

  Reikvam, H ^a,b   Oyan A M ^a,b   Kalland, K H ^a,b   Hovland, R ^b   Hatfield, K J ^a   Bruserud, O ^a,b  

^a UNIVERSITY OF BERGEN   (Norway)

^b HAUKELAND UNIVERSITY HOSPITAL   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

COLONY STIMULATING FACTOR 1; CYTOKINE; FLT3 LIGAND; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 1; INTERLEUKIN 3; STEM CELL FACTOR;

ADULT; AGED; ARTICLE; CELL PROLIFERATION; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; IN VITRO STUDY; LEUKEMIA CELL; LEUKEMIA RELAPSE; MAJOR CLINICAL STUDY; MALE; MICROARRAY ANALYSIS; MYELOID LEUKEMIA; SIGNAL TRANSDUCTION;

ADULT; AGED; AGED, 80 AND OVER; AUTOCRINE COMMUNICATION; CELL PROLIFERATION; CLUSTER ANALYSIS; COMPUTATIONAL BIOLOGY; CYTOKINES; FEMALE; FMS-LIKE TYROSINE KINASE 3; GENE DUPLICATION; HUMANS; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; MUTATION; NUCLEAR PROTEINS; SIGNAL TRANSDUCTION; TRANSCRIPTOME; TUMOR CELLS, CULTURED;

EID: 84884696841     PISSN: 09607722     EISSN: 13652184     Source Type: Journal    
DOI: 10.1111/cpr.12057     Document Type: Article

References (30)

1. Estey EH (2012) Acute myeloid leukemia: 2012 update on diagnosis, risk stratification, and management. Am. J. Hematol. 87, 89-99.
2. Welch JS, Ley TJ, Link DC, Miller CA, Larson DE, Koboldt DC et al. (2012) The origin and evolution of mutations in acute myeloid leukemia. Cell 150, 264-278.
3. Lowenberg B, van Putten WL, Touw IP, Delwel R, Santini V (1993) Autonomous proliferation of leukemic cells in vitro as a determinant of prognosis in adult acute myeloid leukemia. N. Engl. J. Med. 328, 614-619.
4. Hunter AE, Rogers SY, Roberts IA, Barrett AJ, Russell N (1993) Autonomous growth of blast cells is associated with reduced survival in acute myeloblastic leukemia. Blood 82, 899-903.
5. Bruserud O, Frostad S, Foss B (1999) In vitro culture of acute myelogenous leukemia blasts: a comparison of four different culture media. J. Hematother. 8, 63-73.
6. Bruserud O, Gjertsen BT, Foss B, Huang TS (2001) New strategies in the treatment of acute myelogenous leukemia (AML): in vitro culture of aml cells-the present use in experimental studies and the possible importance for future therapeutic approaches. Stem Cells 19, 1-11.
7. Bruserud O, Gjertsen BT (2000) New strategies for the treatment of acute myelogenous leukemia: differentiation induction-present use and future possibilities. Stem Cells 18, 157-165.
8. Van Etten RA (2007) Aberrant cytokine signaling in leukemia. Oncogene 26, 6738-6749.
9. Valk PJ, Verhaak RG, Beijen MA, Erpelinck CA, Barjesteh van Waalwijk van Doorn-Khosrovani S, Boer JM et al. (2004) Prognostically useful gene-expression profiles in acute myeloid leukemia. N. Engl. J. Med. 350, 1617-1628.
10. Bullinger L, Dohner K, Bair E, Frohling S, Schlenk RF, Tibshirani R et al. (2004) Use of gene-expression profiling to identify prognostic subclasses in adult acute myeloid leukemia. N. Engl. J. Med. 350, 1605-1616.
11. Bruserud O, Hovland R, Wergeland L, Huang TS, Gjertsen BT (2003) Flt3-mediated signaling in human acute myelogenous leukemia (AML) blasts: a functional characterization of Flt3-ligand effects in AML cell populations with and without genetic Flt3 abnormalities. Haematologica 88, 416-428.
12. Bruserud O, Ryningen A, Wergeland L, Glenjen NI, Gjertsen BT (2004) Osteoblasts increase proliferation and release of pro-angiogenic interleukin 8 by native human acute myelogenous leukemia blasts. Haematologica 89, 391-402.
13. Stapnes C, Doskeland AP, Hatfield K, Ersvaer E, Ryningen A, Lorens JB et al. (2007) The proteasome inhibitors bortezomib and PR-171 have antiproliferative and proapoptotic effects on primary human acute myeloid leukaemia cells. Br. J. Haematol. 136, 814-828.
14. Reikvam H, Hatfield KJ, Ersvaer E, Hovland R, Skavland J, Gjertsen BT et al. (2012) Expression profile of heat shock proteins in acute myeloid leukaemia patients reveals a distinct signature strongly associated with FLT3 mutation status - consequences and potentials for pharmacological intervention. Br. J. Haematol. 156, 468-480.
15. Oyan AM, Anensen N, Bo TH, Stordrange L, Jonassen I, Bruserud O et al. (2009) Genes of cell-cell interactions, chemotherapy detoxification and apoptosis are induced during chemotherapy of acute myeloid leukemia. BMC Cancer 9, 77.
16. Stavrum AK, Petersen K, Jonassen I, Dysvik B (2008) Analysis of gene-expression data using J-Express. Curr. Protoc. Bioinformatics 7, 7 3.
17. Dysvik B, Jonassen I (2001) J-Express: exploring gene expression data using Java. Bioinformatics 17, 369-370.
18. Lazarus HM, Perez WS, Klein JP, Kollman C, Bate-Boyle B, Bredeson CN et al. (2006) Autotransplantation versus HLA-matched unrelated donor transplantation for acute myeloid leukaemia: a retrospective analysis from the Center for International Blood and Marrow Transplant Research. Br. J. Haematol. 132, 755-769.
19. Ferrara F, Palmieri S, Mele G (2004) Prognostic factors and therapeutic options for relapsed or refractory acute myeloid leukemia. Haematologica 89, 998-1008.
20. Yang XJ, Ullah M (2007) MOZ and MORF, two large MYSTic HATs in normal and cancer stem cells. Oncogene 26, 5408-5419.
21. Morrison AA, Viney RL, Ladomery MR (2008) The post-transcriptional roles of WT1, a multifunctional zinc-finger protein. Biochim. Biophys. Acta 1785, 55-62.
22. Katsumoto T, Yoshida N, Kitabayashi I (2008) Roles of the histone acetyltransferase monocytic leukemia zinc finger protein in normal and malignant hematopoiesis. Cancer Sci. 99, 1523-1527.
23. Razin SV, Borunova VV, Maksimenko OG, Kantidze OL (2012) Cys2His2 zinc finger protein family: classification, functions, and major members. Biochemistry 77, 217-226.
24. Hatfield KJ, Hovland R, Oyan AM, Kalland KH, Ryningen A, Gjertsen BT et al. (2008) Release of angiopoietin-1 by primary human acute myelogenous leukemia cells is associated with mutations of nucleophosmin, increased by bone marrow stromal cells and possibly antagonized by high systemic angiopoietin-2 levels. Leukemia 22, 287-293.
25. Kayser S, Schlenk RF, Londono MC, Breitenbuecher F, Wittke K, Du J et al. (2009) Insertion of FLT3 internal tandem duplication in the tyrosine kinase domain-1 is associated with resistance to chemotherapy and inferior outcome. Blood 114, 2386-2392.
26. Schlenk RF, Dohner K, Krauter J, Frohling S, Corbacioglu A, Bullinger L et al. (2008) Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia. N. Engl. J. Med. 358, 1909-1918.
27. Stirewalt DL, Kopecky KJ, Meshinchi S, Engel JH, Pogosova-Agadjanyan EL, Linsley J et al. (2006) Size of FLT3 internal tandem duplication has prognostic significance in patients with acute myeloid leukemia. Blood 107, 3724-3726.
28. Bruserud O, Gjertsen BT, von Volkman HL (2000) In vitro culture of human acute myelogenous leukemia (AML) cells in serum-free media: studies of native AML blasts and AML cell lines. J. Hematother. Stem Cell Res. 9, 923-932.
29. Bruserud O, Ulvestad E (1999) Effects of gamma-irradiation on acute myelogenous leukemia blasts: in vitro studies of proliferation, constitutive cytokine secretion, and accessory cell function during T cell activation. J. Hematother. Stem Cell Res. 8, 431-441.
30. Döhner H, Estey EH, Amadori S, Appelbaum FR, Buchner T, Burnett AK et al. (2010) Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood 115, 453-474.